Amgen's Humira Patent Challenge May Move To Court After PTO Board Declines Review

 
• By Brenda Sandburg

Patent Trial and Appeal Board denies Amgen's inter partes review petitions seeking to knock out Humira formulation patents.

More from United States

More from North America